Bubs Australia (BUB) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
8 Apr, 2026Strategic direction and leadership
Introduced a highly experienced executive team focused on disciplined execution, global expansion, and risk management.
Emphasized robust governance, a strategic reset, and a unified operating cadence, resulting in doubled revenue and inaugural profits.
Outlined a sequenced execution plan targeting value creation, brand equity, and financial strength.
Board and leadership are deeply engaged in capital allocation discipline and performance culture.
Proven platform with high barriers to entry, strong margins, and diversified markets.
Market positioning and growth strategy
Focused on premium infant nutrition, leveraging Australian heritage, clean label credentials, and gentle digestion.
Leading in goat formula, with expansion into toddler, adult nutrition, and supplements.
Proven ability to scale in Australia, China, and the U.S., with targeted consumer engagement and digital strategies.
Targeting digitally savvy, higher-income urban parents for brand advocacy and repeat purchase.
Purpose centers on clean, gentle nutrition and lifelong wellbeing, with a mission to be trusted globally.
Financial performance and guidance
FY26 revenue guidance upgraded to AUD 120–125 million (USD $120–125M), reflecting 22–27% growth over prior year.
Underlying EBIT/EBITDA guidance for FY26 is AUD 9–11 million, with 1H FY26 EBITDA at $4.4M.
Achieved 26% revenue CAGR from FY23 to FY26, with strong operating leverage and low debt.
Capital-light business model and disciplined investment drive positive cash flow and margin growth.
Expecting to be operating cash flow positive by FY27, with disciplined working capital management.
Latest events from Bubs Australia
- Revenue up 14% to $55.5M, led by US growth; gross margin 48%; FY26 outlook upgraded.BUB
H1 202627 Feb 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Revenue up 29% to $102.5M, USA leads growth, positive EBITDA, and FDA submission for US access.BUB
H2 202523 Nov 2025 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025